Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRN300
MIFTS: 65

Coronary Heart Disease 1

Categories: Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Coronary Heart Disease 1

About this section

MalaCards integrated aliases for Coronary Heart Disease 1:

Name: Coronary Heart Disease 1 57 29
Coronary Heart Disease 57 76 29 55 6 63 73
Coronary Heart Disease, Susceptibility to, 1 57 73
Heart, Coronary, Disease, Susceptibility to, Type 1 40
Coronary Heart Disease, Susceptibility to 57
Coronary Arteriosclerosis 73
Coronary Artery Disease 73
Chds1 57

Classifications:

MalaCards categories:
Global: Genetic diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 57 607339
Sources

Summaries for Coronary Heart Disease 1

About this section
PubMed Health : 63 About coronary heart disease: Coronary heart disease (CHD) is a disease in which a waxy substance called plaque (plak) builds up inside the coronary arteries. These arteries supply oxygen-rich blood to your heart muscle.When plaque builds up in the arteries, the condition is called atherosclerosis (ATH-er-o-skler-O-sis). The buildup of plaque occurs over many years.

MalaCards based summary : Coronary Heart Disease 1, also known as coronary heart disease, is related to coronary heart disease 2 and coronary heart disease 4, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Coronary Heart Disease 1 is APOC3 (Apolipoprotein C3), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Lipoprotein metabolism. The drugs Angiotensin II and Olmesartan have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 76 Coronary artery disease (CAD), also known as ischemic heart disease (IHD), refers to a group of diseases... more...

Description from OMIM: 607339
Sources

Related Diseases for Coronary Heart Disease 1

About this section

Diseases in the Coronary Heart Disease 5 family:

Coronary Heart Disease 3 Coronary Heart Disease 1
Coronary Heart Disease 2 Coronary Heart Disease 4
Coronary Heart Disease 7 Coronary Heart Disease 8
Coronary Heart Disease 9 Coronary Heart Disease 6

Diseases related to Coronary Heart Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 coronary heart disease 2 11.4
2 coronary heart disease 4 11.4
3 coronary heart disease 5 11.4
4 coronary heart disease 3 11.3
5 coronary heart disease 7 11.3
6 coronary heart disease 8 11.3
7 coronary heart disease 9 11.3
8 coronary heart disease 6 11.3
9 malignant otitis externa 10.9 CRP INS
10 xanthoma disseminatum 10.9 APOB APOE
11 moderate and severe traumatic brain injury 10.9 ACE APOE
12 fetal macrosomia 10.8 APOA1 APOB INS
13 leukodystrophy, hypomyelinating, 3 10.8 APOA1 APOB APOE
14 hypolipoproteinemia 10.8 APOA1 APOB APOE
15 systolic heart failure 10.8 ACE ADRB1 CRP
16 hyperlipidemia, combined, 1 10.8 APOB APOC3
17 familial lcat deficiency 10.8 APOA1 APOE
18 cerebral atherosclerosis 10.7 ACE APOA1 APOE
19 hypercholesterolemia, autosomal dominant, type b 10.7 APOB APOE LDLR
20 peripheral artery disease 10.7 ACE APOB CRP
21 generalized atherosclerosis 10.7 ACE APOE CRP
22 marek disease 10.7 ACE HMGCR
23 hyperlipoproteinemia, type v 10.7 APOE INS
24 uremia 10.7 APOC3 CRP INS
25 aortic valve disease 1 10.7 ACE APOB CRP
26 lipoprotein glomerulopathy 10.7 APOB APOE LDLR
27 hemorrhage, intracerebral 10.7 ACE APOE HMGCR
28 hyperlipoproteinemia, type iv 10.7 APOA1 APOB APOC3 APOE
29 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.7 CRP INS
30 hyperuricemia 10.6 APOB CRP INS
31 prediabetes syndrome 10.6 APOB COG2 CRP INS
32 smith-lemli-opitz syndrome 10.6 APOE HMGCR LDLR
33 overnutrition 10.6 APOB COG2 CRP INS
34 carotid stenosis 10.6 ACE APOE CRP
35 microvascular complications of diabetes 5 10.6 ACE INS PON1
36 peripheral vascular disease 10.6 ACE APOA1 APOB CRP
37 abetalipoproteinemia 10.6 APOA1 APOB APOE CETP
38 tangier disease 10.6 APOA1 APOB APOE CETP
39 hepatic lipase deficiency 10.6 APOA1 APOE
40 defective apolipoprotein b-100 10.6 APOB APOE HMGCR LDLR
41 hypobetalipoproteinemia, familial, 1 10.6 APOA1 APOB APOE LDLR
42 acute myocardial infarction 10.6 ACE ADRB1 APOA1 CRP
43 homozygous familial hypercholesterolemia 10.5 APOB APOE HMGCR LDLR
44 urinary system disease 10.5 ACE CRP INS
45 vascular dementia 10.5 ACE APOE PON1
46 xanthomatosis 10.5 APOB APOE HMGCR LDLR
47 hyperlipidemia, familial combined 10.5 APOA1 APOB APOC3 APOE COG2
48 chronic kidney failure 10.5 ACE CRP HMGCR INS
49 macular degeneration, age-related, 1 10.5 APOB APOE CRP CX3CR1
50 sleep apnea 10.5 ACE APOE CRP INS

Graphical network of the top 20 diseases related to Coronary Heart Disease 1:



Diseases related to Coronary Heart Disease 1
Sources

Symptoms & Phenotypes for Coronary Heart Disease 1

About this section

Clinical features from OMIM:

607339

UMLS symptoms related to Coronary Heart Disease 1:


angina pectoris, chest pain, edema, tremor, substernal pain, equilibration disorder

GenomeRNAi Phenotypes related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.5 APOA1 APOB APOC3 APOE CETP HMGCR
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE LDLR

MGI Mouse Phenotypes related to Coronary Heart Disease 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 CRP CX3CR1 INS LDLR PON1 ACE
2 homeostasis/metabolism MP:0005376 9.73 COG2 CRP CX3CR1 HMGCR INS LDLR
3 liver/biliary system MP:0005370 9.17 HMGCR INS LDLR ACE APOA1 APOB
Sources

Drugs & Therapeutics for Coronary Heart Disease 1

About this section

PubMedHealth treatment related to Coronary Heart Disease 1: 63

Treatments for coronary heart disease (CHD) include lifestyle changes, medicines, and medical procedures. Treatment goals may include:Relieving symptoms.Reducing risk factors in an effort to slow, stop, or reverse the buildup of plaque.Lowering the risk of blood clots forming. (Blood clots can cause a heart attack.)Widening or bypassing clogged arteries.Preventing complications of CHD.

Drugs for Coronary Heart Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1071)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
2
Olmesartan Approved, Investigational Phase 4,Phase 2 144689-24-7, 144689-63-4 158781 130881
3
Menthol Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
4
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
7
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
8
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
9
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55142-85-3 5472
10
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 73963-72-1 2754
11
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
12
Tirofiban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144494-65-5 60947
13
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 9552079 2713
14
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
15
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
16
Trimetazidine Approved, Investigational Phase 4,Not Applicable 5011-34-7
17
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
18
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
19
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 23994
20
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 88150-42-9 2162
21
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
22
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
23
Fluvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 93957-54-1 1548972
24
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142387-99-3, 95635-55-5 56959
25
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
26
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 6691 54678486
27
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-47-3 27668
28
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
29
Pitavastatin Approved Phase 4,Phase 3,Not Applicable 147511-69-1, 147526-32-7 6366718 5282452
30
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 122320-73-4 77999
31
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 163222-33-1 150311
32
Lovastatin Approved, Investigational Phase 4,Phase 2,Phase 3 75330-75-5 53232
33
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 72956-09-3 2585
34
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
35
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
36
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-32-2 3108
37
Regadenoson Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 313348-27-5 219024
38
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
39
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 113775-47-6 68602 5311068
40
Etomidate Approved Phase 4 33125-97-2 36339 667484
41
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
42
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
43
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28523-86-6 5206
44
Sufentanil Approved, Investigational Phase 4,Not Applicable 56030-54-7 41693
45
Nicorandil Approved, Investigational Phase 4,Phase 3,Not Applicable 65141-46-0 47528
46
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 64-17-5 702
47
Thrombin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
48
Vorapaxar Approved Phase 4,Phase 3,Phase 2,Phase 1 618385-01-6
49
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 37350-58-6, 51384-51-1 4171
50
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772

Interventional clinical trials:

(show top 50) (show all 7667)
# Name Status NCT ID Phase Drugs
1 Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
2 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
3 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
4 Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease-2 Unknown status NCT01664858 Phase 4
5 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
6 Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
7 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
8 Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease Unknown status NCT02514642 Phase 4 low-dose ticagrelor;Clopidogrel
9 The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
10 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
11 Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
12 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques Unknown status NCT01773512 Phase 4 Rosuvastatin
13 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
14 Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
15 Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
16 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
17 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
18 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
19 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
20 The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
21 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
22 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM) Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
23 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
24 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
25 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
26 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
27 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
28 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
29 Fluvastatin AmelIorates aTHerosclerosis Study Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
30 Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
31 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
32 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
33 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
34 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
35 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
36 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
37 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
38 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
39 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
40 PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
41 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
42 Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI Unknown status NCT01781715 Phase 4
43 Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients Unknown status NCT01807078 Phase 4 Ezetimibe
44 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
45 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
46 Plasma and Platelet microRNAs in Clopidogrel Low Response Patients Unknown status NCT02447809 Phase 4 Clopidogrel;acetylsalicylic acid (ASA)
47 Periodontal Therapy in Coronary Artery Patients Unknown status NCT01609725 Phase 4
48 A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization Unknown status NCT01157455 Phase 4 Aspirin;Clopidogrel;Heparin or Bivalirudin
49 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4
50 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4

Search NIH Clinical Center for Coronary Heart Disease 1

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Coronary Heart Disease 1

About this section

Genetic tests related to Coronary Heart Disease 1:

# Genetic test Affiliating Genes
1 Coronary Heart Disease 1 29 CX3CR1
2 Coronary Heart Disease 29
Sources

Anatomical Context for Coronary Heart Disease 1

About this section

MalaCards organs/tissues related to Coronary Heart Disease 1:

41
Heart, Endothelial, Testes, Bone, Kidney, Bone Marrow, Breast
Sources

Publications for Coronary Heart Disease 1

About this section

Articles related to Coronary Heart Disease 1:

(show top 50) (show all 2239)
# Title Authors Year
1
Human cytomegalovirus infection and coronary heart disease: a systematic review. ( 29409508 )
2018
2
The association of neck circumference with incident congestive heart failure and coronary heart disease mortality in a community-based population with or without sleep-disordered breathing. ( 29855261 )
2018
3
Fine particulate matter and incident coronary heart disease in the REGARDS cohort. ( 29447790 )
2018
4
A study on the relationship between plasma selenium concentration and erythrocyte deformability in rat models of coronary heart disease. ( 29442482 )
2018
5
Adiposity-Mortality Relationships in Type 2 Diabetes, Coronary Heart Disease and Cancer Subgroups in the UK Biobank, and Their Modification by Smoking. ( 29970414 )
2018
6
Suicidal ideation in patients with coronary heart disease and hypertension: Baseline results from the DEPSCREEN-INFO clinical trial. ( 29971880 )
2018
7
National Prevalence of Self-Reported Coronary Heart Disease and Chronic Stable Angina Pectoris: Factor Analysis of the Underlying Cardiometabolic Risk Factors in the Fourth Round of the SuRFNCD-2011. ( 29434010 )
2018
8
Circulating MiR-146a May be a Potential Biomarker of Coronary Heart Disease in Patients with Subclinical Hypothyroidism. ( 29357324 )
2018
9
PON2 and PPARG polymorphisms as biomarkers of risk for coronary heart disease. ( 29441810 )
2018
10
The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial): A randomized clinical trial in secondary prevention of coronary heart disease in a multiethnic Australian population: Study protocol. ( 29966802 )
2018
11
ENPP1 K121Q (rs1044498a88Ca88>a88A) genetic polymorphism confers a high risk of susceptibility to coronary heart disease: A PRISMA-compliant article. ( 29979387 )
2018
12
The association of inflammatory markers and periodontal indexes with the risk of coronary heart disease in Chinese patients with type 2 diabetes mellitus. ( 29111278 )
2018
13
A Literature Review of Antithrombotic Therapy for Patients of Venous Thromboembolic Events with Comorbidity of Coronary Heart Disease. ( 29976282 )
2018
14
'Heart disease never entered my head' Women's Understanding of Coronary Heart Disease Risk Factors. ( 29969829 )
2018
15
Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583. ( 29448977 )
2018
16
Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia. ( 29968891 )
2018
17
Peripheral vascular disease risk in diabetic individuals without coronary heart disease. ( 29801688 )
2018
18
Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: Results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. ( 28534422 )
2017
19
Tall stature in coronary heart disease patients is associated with decreased risk of frailty in late life. ( 27539907 )
2017
20
Adipokine and Cytokine Profiles of Epicardial and Subcutaneous Adipose Tissue in Patients with Coronary Heart Disease. ( 28948552 )
2017
21
Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus. ( 28588089 )
2017
22
Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease. ( 27097870 )
2017
23
Hyperuricemia does not seem to be an independent risk factor for coronary heart disease. ( 28917080 )
2017
24
Predictive Effects of Circulating miR-221, miR-130a and miR-155 for Coronary Heart Disease: A Multi-Ethnic Study in China. ( 28628920 )
2017
25
PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease. ( 28885323 )
2017
26
Variants in the SMARCA4 gene was associated with coronary heart disease susceptibility in Chinese han population. ( 28055962 )
2017
27
Accounting for Time-varying Confounding in the Relation between Obesity and Coronary Heart Disease: Analysis with G-estimation, the Atherosclerosis Risk in Communities (ARIC) study. ( 29155924 )
2017
28
Associations of Vitamin D-Binding Globulin and Bioavailable Vitamin D Concentrations With Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA). ( 28472285 )
2017
29
Ultra-sensitive troponin I is an independent predictor of incident coronary heart disease in the general population. ( 28585121 )
2017
30
Association of low serum albumin concentration and adverse cardiovascular events in stable coronary heart disease. ( 28413113 )
2017
31
Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis. ( 28514697 )
2017
32
Decreased frequencies and impaired functions of the CD31(+) subpopulation in Treg cells associated with decreased FoxP3 expression and enhanced Treg cell defects in patients with coronary heart disease. ( 27997991 )
2017
33
Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. ( 28411266 )
2017
34
[Influence of PCSK9 gene E670G polymorphism on the risk of atherosclerotic coronary heart disease and plasma lipid level]. ( 28981947 )
2017
35
PPBP and DEFA1/DEFA3 genes in hyperlipidaemia as feasible synergistic inflammatory biomarkers for coronary heart disease. ( 28420383 )
2017
36
Carotid atherosclerosis and its relationship to coronary heart disease and stroke risk in patients with type 2 diabetes mellitus. ( 28953658 )
2017
37
Cluster analysis for syndromes of real-world coronary heart disease with angina pectoris. ( 29209917 )
2017
38
LipoproteinA (a) and coronary heart disease - is there an efficient secondary prevention? ( 28233270 )
2017
39
Glutathione S-Transferase T1 (GSTT1) Null Polymorphism, Smoking, and Their Interaction in Coronary Heart Disease: A Comprehensive Meta-Analysis. ( 27686690 )
2017
40
Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: prospective cohort study. ( 28465308 )
2017
41
Association between Toll-like receptor 4 Asp299Gly polymorphism and coronary heart disease susceptibility. ( 28793055 )
2017
42
Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) analysis. ( 28625382 )
2017
43
Association between hemorrhoid and risk of coronary heart disease: A nationwide population-based cohort study. ( 28767586 )
2017
44
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. ( 28566218 )
2017
45
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. ( 28506971 )
2017
46
Association between chemokine CXC ligand 12 gene polymorphism (rs1746048) and coronary heart disease: A MOOSE-compliant meta-analysis. ( 28614256 )
2017
47
Association between circulating microRNA-208a and severity of coronary heart disease. ( 28554251 )
2017
48
<i>PCSK9</i> Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites. ( 28768753 )
2017
49
Association between PPAP2B gene polymorphisms and coronary heart disease susceptibility in Chinese Han males and females. ( 28061459 )
2017
50
Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population. ( 28687336 )
2017
Sources

Variations for Coronary Heart Disease 1

About this section

ClinVar genetic disease variations for Coronary Heart Disease 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 APOC3 NM_000040.2(APOC3): c.55C> T (p.Arg19Ter) single nucleotide variant Pathogenic rs76353203 GRCh37 Chromosome 11, 116701353: 116701353
2 APOC3 NM_000040.2(APOC3): c.55C> T (p.Arg19Ter) single nucleotide variant Pathogenic rs76353203 GRCh38 Chromosome 11, 116830637: 116830637
3 APOC3 NM_000040.2(APOC3): c.55+1G> A single nucleotide variant Pathogenic,protective rs138326449 GRCh38 Chromosome 11, 116830638: 116830638
4 APOC3 NM_000040.2(APOC3): c.55+1G> A single nucleotide variant Pathogenic,protective rs138326449 GRCh37 Chromosome 11, 116701354: 116701354
5 APOC3 NM_000040.2(APOC3): c.127G> A (p.Ala43Thr) single nucleotide variant Pathogenic,protective rs147210663 GRCh38 Chromosome 11, 116830844: 116830844
6 APOC3 NM_000040.2(APOC3): c.127G> A (p.Ala43Thr) single nucleotide variant Pathogenic,protective rs147210663 GRCh37 Chromosome 11, 116701560: 116701560
7 APOC3 NM_000040.2(APOC3): c.179+1G> T single nucleotide variant Pathogenic,protective rs140621530 GRCh38 Chromosome 11, 116830897: 116830897
8 APOC3 NM_000040.2(APOC3): c.179+1G> T single nucleotide variant Pathogenic,protective rs140621530 GRCh37 Chromosome 11, 116701613: 116701613
Sources

Expression for Coronary Heart Disease 1

About this section
Search GEO for disease gene expression data for Coronary Heart Disease 1.
Sources

Pathways for Coronary Heart Disease 1

About this section

Pathways related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Metabolism of water-soluble vitamins and cofactors 66
Show member pathways
 12.37 APOA1 APOB APOC3 APOE LDLR
2
Lipoprotein metabolism 66
Show member pathways
 12.27 APOA1 APOB APOC3 APOE CETP LDLR
3
Metabolism of fat-soluble vitamins 66
Show member pathways
 12.05 APOA1 APOB APOC3 APOE LDLR
4
Folate Metabolism 1
Show member pathways
 11.97 APOA1 APOB APOE CRP INS LDLR
5
Binding and Uptake of Ligands by Scavenger Receptors 66
Show member pathways
 11.63 APOA1 APOB APOE
6
Sterol Regulatory Element-Binding Proteins (SREBP) signalling 1
11.44 HMGCR INS LDLR
7
Statin Pathway 1
Show member pathways
 11.24 APOA1 APOB APOC3 APOE CETP HMGCR
8
A-beta Pathways: Uptake and Degradation 65
10.76 ACE APOE CX3CR1 LDLR
9
SREBF and miR33 in cholesterol and lipid homeostasis 1
10.74 HMGCR LDLR
Sources

GO Terms for Coronary Heart Disease 1

About this section

Cellular components related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 early endosome GO:0005769 9.88 ADRB1 APOA1 APOB APOC3 APOE LDLR
2 endoplasmic reticulum lumen GO:0005788 9.83 APOA1 APOB APOE INS
3 clathrin-coated endocytic vesicle membrane GO:0030669 9.65 APOB APOE LDLR
4 high-density lipoprotein particle GO:0034364 9.62 APOA1 APOE CETP PON1
5 endocytic vesicle lumen GO:0071682 9.61 APOA1 APOB APOE
6 very-low-density lipoprotein particle GO:0034361 9.56 APOA1 APOB APOC3 APOE
7 endosome lumen GO:0031904 9.54 APOB INS
8 spherical high-density lipoprotein particle GO:0034366 9.54 APOA1 APOC3 PON1
9 discoidal high-density lipoprotein particle GO:0034365 9.49 APOA1 APOE
10 low-density lipoprotein particle GO:0034362 9.46 APOA1 APOB APOE LDLR
11 chylomicron GO:0042627 9.26 APOA1 APOB APOC3 APOE
12 intermediate-density lipoprotein particle GO:0034363 8.92 APOA1 APOB APOC3 APOE
13 extracellular region GO:0005576 10.16 ACE APOA1 APOB APOC3 APOE CETP
14 extracellular space GO:0005615 10.16 ACE APOA1 APOB APOC3 APOE CETP

Biological processes related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.99 APOA1 APOB APOE INS
2 receptor-mediated endocytosis GO:0006898 9.97 APOA1 APOB APOE LDLR
3 retinoid metabolic process GO:0001523 9.91 APOA1 APOB APOC3 APOE
4 lipid transport GO:0006869 9.91 APOA1 APOB APOC3 APOE CETP LDLR
5 steroid metabolic process GO:0008202 9.88 APOA1 APOB APOE CETP HMGCR LDLR
6 cholesterol transport GO:0030301 9.86 APOA1 APOB CETP LDLR
7 triglyceride homeostasis GO:0070328 9.85 APOA1 APOC3 APOE CETP
8 triglyceride catabolic process GO:0019433 9.84 APOA1 APOB APOC3 APOE
9 phospholipid transport GO:0015914 9.83 APOA1 CETP LDLR
10 cholesterol biosynthetic process GO:0006695 9.82 APOA1 APOE HMGCR
11 triglyceride metabolic process GO:0006641 9.81 APOC3 APOE CETP
12 positive regulation of lipid biosynthetic process GO:0046889 9.8 APOA1 APOE INS
13 cholesterol efflux GO:0033344 9.8 APOA1 APOB APOC3 APOE
14 phosphatidylcholine metabolic process GO:0046470 9.79 APOA1 CETP PON1
15 low-density lipoprotein particle remodeling GO:0034374 9.78 APOB APOE CETP
16 reverse cholesterol transport GO:0043691 9.78 APOA1 APOC3 APOE CETP
17 phospholipid efflux GO:0033700 9.77 APOA1 APOC3 APOE
18 negative regulation of blood vessel diameter GO:0097756 9.77 CRP HMGCR INS
19 very-low-density lipoprotein particle remodeling GO:0034372 9.76 APOA1 APOE CETP
20 high-density lipoprotein particle remodeling GO:0034375 9.76 APOA1 APOC3 APOE CETP
21 regulation of Cdc42 protein signal transduction GO:0032489 9.75 APOA1 APOC3 APOE
22 lipoprotein biosynthetic process GO:0042158 9.74 APOA1 APOB APOE
23 cholesterol homeostasis GO:0042632 9.73 APOA1 APOB APOC3 APOE CETP LDLR
24 positive regulation of nitric-oxide synthase activity GO:0051000 9.71 APOE INS
25 negative regulation of lipid catabolic process GO:0050995 9.71 APOC3 INS
26 positive regulation of cholesterol efflux GO:0010875 9.7 APOE PON1
27 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.7 CETP CRP
28 fatty acid homeostasis GO:0055089 9.7 APOE INS
29 high-density lipoprotein particle assembly GO:0034380 9.7 APOA1 APOE
30 lipoprotein catabolic process GO:0042159 9.7 APOB APOE LDLR
31 regulation of protein metabolic process GO:0051246 9.69 APOE LDLR
32 regulation of cholesterol metabolic process GO:0090181 9.69 APOE LDLR
33 very-low-density lipoprotein particle assembly GO:0034379 9.69 APOB APOC3
34 positive regulation of cholesterol esterification GO:0010873 9.68 APOA1 APOE
35 high-density lipoprotein particle clearance GO:0034384 9.68 APOA1 APOE
36 phospholipid homeostasis GO:0055091 9.68 APOA1 CETP
37 neuron projection regeneration GO:0031102 9.67 APOA1 APOE
38 negative regulation of long-term synaptic potentiation GO:1900272 9.67 APOE CX3CR1
39 chylomicron assembly GO:0034378 9.67 APOA1 APOB APOC3 APOE
40 regulation of cholesterol transport GO:0032374 9.66 APOA1 APOE
41 cholesterol import GO:0070508 9.66 APOA1 LDLR
42 very-low-density lipoprotein particle clearance GO:0034447 9.65 APOB APOE
43 positive regulation of dendritic spine maintenance GO:1902952 9.64 APOE INS
44 negative regulation of very-low-density lipoprotein particle remodeling GO:0010903 9.63 APOA1 APOC3
45 response to caloric restriction GO:0061771 9.63 APOE LDLR
46 chylomicron remodeling GO:0034371 9.62 APOA1 APOB APOC3 APOE
47 chylomicron remnant clearance GO:0034382 9.46 APOB APOC3 APOE LDLR
48 lipoprotein metabolic process GO:0042157 9.35 APOA1 APOB APOC3 APOE LDLR
49 cholesterol metabolic process GO:0008203 9.17 APOA1 APOB APOE CETP HMGCR LDLR
50 lipid metabolic process GO:0006629 10.11 APOA1 APOB APOC3 APOE CETP HMGCR

Molecular functions related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.8 APOA1 APOB APOC3 APOE CETP
2 amyloid-beta binding GO:0001540 9.67 APOA1 APOE LDLR
3 cholesterol binding GO:0015485 9.56 APOA1 APOC3 APOE CETP
4 phospholipid binding GO:0005543 9.55 APOA1 APOB APOC3 APOE PON1
5 phospholipid transporter activity GO:0005548 9.52 APOA1 CETP
6 low-density lipoprotein particle binding GO:0030169 9.51 CRP LDLR
7 low-density lipoprotein particle receptor binding GO:0050750 9.5 APOB APOE CRP
8 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.48 APOA1 APOE
9 lipoprotein particle binding GO:0071813 9.46 APOA1 APOE
10 lipase inhibitor activity GO:0055102 9.43 APOA1 APOC3
11 high-density lipoprotein particle receptor binding